Coherus OncologyFRA:8C5 +0.80%45 Days Payable is 254.42 as of Mar. 2026, which is 27% above its 10-year median of 199.55. GuruFocus rates FRA:8C5 with a GF Score™ of 45/100 and a GF Value™ of €0.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 702 Biotechnology companies, Coherus Oncology ranks better than 81.77% on this metric.
The historical rank and industry rank for Coherus Oncology's Days Payable or its related term are showing as below:
FRA:8C5'
s Days Payable Range Over the Past 10 Years
Min: 53.66 Med: 199.55 Max: 1331.58
Current: 608.56
During the past 13 years, Coherus Oncology's highest Days Payable was 1331.58. The lowest was 53.66. And the median was 199.55.
FRA:8C5's Days Payable is ranked better than 81.77% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs FRA:8C5: 608.56
Coherus Oncology's Days Payable
declined
from Mar. 2025 (1,209.14) to Mar. 2026 (254.42).
It may suggest that Coherus Oncologyaccelerated paying its suppliers.
Coherus Oncology Days Payable Related Terms
Coherus Oncology Days Payable Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: Days Payable Comparison
For the Biotechnology subindustry, Coherus Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Coherus Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Days Payable of 254.42 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Coherus Oncology and its competitors. This is 27% above median its historical median of 199.55. Over the past decade, Coherus Oncology's Days Payable has ranged from 53.66 to 1,331.58. According to the industry distribution chart, Coherus Oncology ranks #128 out of 702 companies in the Biotechnology industry, placing it in the top 18.2%.
Is Coherus Oncology's Days Payable too high?
Coherus Oncology's current Days Payable of 254.42 is 27% above median its 10-year median of 199.55. Over the past 10 years, this metric has ranged from a low of 53.66 to a high of 1,331.58. The Biotechnology industry median Days Payable is 113.56. Coherus Oncology's value of 254.42 is 124% above this industry median. Based on the distribution chart, Coherus Oncology ranks #128 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Days Payable compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #128 out of 702 companies for Days Payable. This places Coherus Oncology in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Coherus Oncology's value of 254.42 is 124% above this benchmark. Historically, Coherus Oncology's own Days Payable has ranged from 53.66 to 1,331.58 over the past decade. While the company's 10-year median is 199.55 vs. the industry median of 113.56, Coherus Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Days Payable of 254.42 is 124% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Days Payable is 254.42, which is 27% above median its own 10-year median of 199.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.67, compared to a current price of €1.26 — trading 87.3% above its estimated fair value. The current Days Payable is 254.42, which is 27% above median its 10-year median of 199.55 and 124% above the Biotechnology industry median of 113.56. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Days Payable is 254.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.26 is trading 87.3% above its estimated GF Value™ of €0.67.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Days Payable: 254.42 (27% above median its 10-year median of 199.55)
GF Value™: €0.67 vs. price of €1.26 (87.3% above fair value)
Industry Position: 124% above the Biotechnology median (#128 of 702)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
